Abstract 239P
Background
Oral cancer surgery includes radical resections of the mandible and tongue, affecting the functional swallowing outcomes. However, risk factors and swallowing outcomes are not the same for all subsites of oral cancer. The present study aimed to assess the difference in patient-reported swallowing function and quality of life after primary surgical resection in tongue vs bucco- alveolar complex (BAC) malignancies.
Methods
Study included oral cancer patients requiring mandibulectomy for BAC subsite and at least hemi-glossectomy for tongue, all reconstructed with pedicle flaps at our institute from Dec 2019 to Dec 2021. The Sydney Swallow Questionnaire (SSQ) and Functional oral intake scale (FOIS) were used to assess swallowing outcomes after six months DFS. WHO BREF questionnaire was used to assess health-related quality of life.
Results
The final analysis included 66 patients. The median age was 48 yrs and majority are males (92.4%). BAC constituted 63.6%, and tongue lesions were 36.4%. Tumours with cT3 and T4 are 59% of BAC and 46% of tongue lesions. In BAC, 85% underwent segmental mandibulectomy, and 87% of tongue lesions were treated with hemiglossectomy. 85.7% of BAC and 92% of tongue lesions received adjuvant radiation. Trismus and xerostomia were present in 71.4%, 85% in BAC and 50%, 75% in tongue lesions, respectively. The mean SSQ score was (282.6, SD= 95), (222.5, SD=96) BAC and tongue, respectively. Advanced T stage (p=0.07), Multimodality treatment (p=0.01), lymphedema (p=0.03), Trismus (p=0.01), Dysgeusia (p=0.01), xerostomia (p=0.01) in BAC lesions. Advanced T stage (p=0.007), Multimodality treatment (p=0.04), lymphedema (p=0.03), Dysgeusia (p=0.01) in tongue lesions are associated with poor outcomes. Almost 88% of BAC lesions required special food preparation for swallowing (FOIS 5). However, only 16.7% of tongue lesions required special preparation. There is a trend toward better health-related quality of life (HRQOL) in tongue lesions.
Conclusions
There is a difference in swallowing results between tongue and BAC cancers. Tongue lesions had more reasonable swallowing outcomes. However, overall, HRQOL is comparable between both subsites.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03